BIOVF (Swedish Orphan Biovitrum AB) Institutional Ownership: 30.46% (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOVF Swedish Orphan Biovitrum AB BIOVF
83 GF Score
Price $48.21
GF Value $37.34
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Institutional Ownership?

Swedish Orphan Biovitrum AB BIOVF 83 Institutional Ownership is 30.46% as of Jul. 30, 2026. GuruFocus rates BIOVF with a GF Score™ of 83/100 and a GF Value™ of $37.34 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Swedish Orphan Biovitrum AB's institutional ownership is 30.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Swedish Orphan Biovitrum AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Swedish Orphan Biovitrum AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Swedish Orphan Biovitrum AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Institutional Ownership Chart

Swedish Orphan Biovitrum AB Historical Data

The historical data trend for Swedish Orphan Biovitrum AB can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 27.86 25.94 25.69 25.60 26.13 26.55 25.76 25.69 25.74 25.36
BIOVF
83GF Score
Swedish Orphan Biovitrum AB BIOVF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 30.46% mean?
Swedish Orphan Biovitrum AB (BIOVF) has a Institutional Ownership of 30.46% as of Jul. 30, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Institutional Ownership too high?
Swedish Orphan Biovitrum AB's current Institutional Ownership is 30.46%. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Institutional Ownership compare to ZTS?
Swedish Orphan Biovitrum AB's Institutional Ownership of 30.46% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Institutional Ownership is 30.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Modestly Overvalued. The stock's GF Value™ is $37.34, compared to a current price of $48.21 — trading 29.1% above its estimated fair value. The current Institutional Ownership is 30.46%. Swedish Orphan Biovitrum AB's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current Institutional Ownership is 30.46% as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $48.21 is trading 29.1% above its estimated GF Value™ of $37.34. GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.

Key valuation signals for BIOVF:

  • Institutional Ownership: 30.46%
  • GF Value™: $37.34 vs. price of $48.21 (29.1% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score

Get the complete analysis for BIOVF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.21
Price
$37.34
GF Value